🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

International Leukemia Target Board

Recruitingn/aAges 0 Years - 25 YearsAllPrincess Maxima Center for Pediatric Oncology
NCT05270096 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician. The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregate

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria 1. The patient has been diagnosed with a R/R hematological malignancy; 2. The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy; 3. The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment; 4. The patients' life expectancy is at least 6 weeks; 5. The patient has undergone any sort of molecular profiling of his/her tumor and the re-sults of this analysis are available; 6. The patient has undergone flow cytometry in a certified lab and results are available; 7. Written informed consent of patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained. Exclusion criteria: none defined
💊

What it tests

  • Advice
📍

Where

7 sites
UH Gent
Ghent, Belgium
Righospitalet
Copenhagen, Denmark
Semmelweis
Budapest, Hungary
Princess Máxima Center for Pediatric Oncology
Utrecht, Netherlands
Vall d'Hebron
Barcelona, Spain
Queen Silvia
Gothenburg, Sweden
Newcastle Hospital
Newcastle, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy